Abstract:BACKGROUND AND OBJECTIVE:Studies on the epidermal growth factor receptor (EGFR) signaling pathways and the therapeutic effects of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have recently proven that targeted therapy has a major role in the treatment of lung cancer. However, the therapeutic effects of EGFR-TKIs on lung cancers with different EGFR mutation subtypes remain unclear. And if there is a significant difference in the effects of EGFR-TKIs, the mechanisms for the difference remain unclear. The aim of this study was to investigate the clinical importance of EGFR mutations in exons 19 and 21 of lung cancer patients and to compare the outcomes of these patients. METHODS:The study recruited 113 patients who had non-small cell lung cancer (NSCLC) with EGFR mutations. EGFR mutations were detected for 47 patients using Real-time PCR or DNA sequencinag. The mutations of the remaining patients were determined using xTag-EGFR liquid chip technology. All stages I-III patients underwent radical resection followed by 4 cycles of postoperative chemotherapy. Patients with pleural metastases underwent pleural biopsy, pleurodesis, and chemotherapy only. Patients with distant metastases underwent biopsy and chemotherapy only. Collected clinical data were analyzed using SPSS 19.0 software. RESULTS:EGFR exon mutations 19 and 21 were found in 56 and 57 patients, respectively. The mean age of patients with exon 19 mutations was lower than the age of the patients with exon 21 mutations (57.02±11.31 years vs 62.25±7.76 years, respectively; P<0.05). The primary tumors of patients with exon 19 mutations were more likely occur in the right lung. There were no significant differences in gender, smoking status, histopathology, level of differentiation, and stage of disease (P>0.05) between the patients with exon 19 and 21 mutations; and survival analysis of 91 (80.5%) patients with complete clinical data found no differences in overall survival. Stratification analysis found out that patients with exon 19 mutations had longer overall survival associated with age>61 years, male gender, ever smoking, and stage IV disease; although the differences were not significant. CONCLUSIONS:Compared to the lung cancer patients with EGFR exon 21 mutations, the patients with EGFR exon 19 mutations were younger, and their primary tumors were more likely to occur in the right lung. There were no significant differences between the lung cancer patients with exon 19 and 21 mutations for overall survival, gender, smoking status, histopathology, level of differentiation, and disease stage.

Mutation of Exon19 and Exon21 of epidermal growth factor receptor and clinical factor in nonsmall cell lung cancer

[Mutations in Exon 19 of EGFR Gene in Non-Small Cell Lung Cancer from Chinese Patients].

[Relationship Between Mutations of Epidermal Growth Factor Receptor Gene and Clinicopathologic Features of Non-Small Cell Lung Cancers].

Clinical significance of EGFR mutations in non-small cell lung cancer

[Epidermal Growth Factor Receptor Gene Mutations and Clinicopathologic Correlation in 309 Patients with Non-Small Cell Lung Cancer].

Cmar_a_200126 6139..6150

The Status of Epidermal Growth Factor Receptor (EGFR) Mutations at Exon 19 and 21 in Chinese Patients with NSCLC

Detection of Genetic Mutation of Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

Detection of EGFR Gene Mutation in Lung Adenocarcinoma and its Clinical Analysis

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Clinicopathological characteristics of epidermal growth factor receptor gene mutation and mutantsite of lung adenocarcinomas patients in Hunan China

Analysis of epidermal growth factor receptor gene mutations in 406 small biopsy samples of lung cancer

Epidermal growth factor receptor mutations in Chinese patients with adenocarcinoma of the lung

Relationship between EGFR gene 19 th and 21 th exons mutation and clinicopathological features, prognosis of lung adenocarcinoma

[Clinical characteristics and outcomes of lung cancer patients  with EGFR mutations in exons 19 and 21].

An exon 19 mutation of EGFR gene in the serum circulating DNA from patients with advanced lung cancer

Pre-and post-chemotherapy mutation status of epidermal growth factor receptor gene in non-small cell lung cancer

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

Mutational Analysis of EGFR in Chinese Patients with NSCLCs

Mutational analysis of exons 19 and 21 of the EGFR gene in lung adenocarcinoma

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer